Furthermore, for addressing a target surface molecule for TNBC therapy, Hu (55) found that Tissue Factor (TF) serves as a potential target for cancer stem cells (CSCs) that can be derived from various sources such as human breast, lung, and ovarian cancer cell lines. The gene discussed is F3; the disease is cancer.